Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial
Authors
Keywords
-
Journal
LANCET ONCOLOGY
Volume 23, Issue 10, Pages 1308-1320
Publisher
Elsevier BV
Online
2022-09-14
DOI
10.1016/s1470-2045(22)00517-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- HERMES: Delivery of a Speedy Prostate Cancer Treatment
- (2022) R. Westley et al. CLINICAL ONCOLOGY
- Estimates of Alpha/Beta (α/β) Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP trial
- (2021) Douglas H. Brand et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial
- (2021) Linda G. W. Kerkmeijer et al. JOURNAL OF CLINICAL ONCOLOGY
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Radiation Dose to the Intraprostatic Urethra Correlates Strongly With Urinary Toxicity After Prostate Stereotactic Body Radiation Therapy: A Combined Analysis of 23 Prospective Clinical Trials
- (2021) Jonathan E. Leeman et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Once‐a‐week or every‐other‐day urethra‐sparing prostate cancer stereotactic body radiotherapy, a randomized phase II trial: 18 months follow‐up results
- (2020) Thomas Zilli et al. Cancer Medicine
- Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial
- (2019) Anders Widmark et al. LANCET
- Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial
- (2019) Douglas H Brand et al. LANCET ONCOLOGY
- Two versus five stereotactic ablative radiotherapy treatments for localized prostate cancer: A quality of life analysis of two prospective clinical trials
- (2019) Yasir Alayed et al. RADIOTHERAPY AND ONCOLOGY
- Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer
- (2017) Charles N. Catton et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer
- (2016) W. Robert Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
- (2016) David Dearnaley et al. LANCET ONCOLOGY
- Minimally Important Difference for the Expanded Prostate Cancer Index Composite Short Form
- (2015) Ted A. Skolarus et al. UROLOGY
- Impact of Dose to the Bladder Trigone on Long-Term Urinary Function After High-Dose Intensity Modulated Radiation Therapy for Localized Prostate Cancer
- (2014) Pirus Ghadjar et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now